Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Cancer

Date Submitted: Nov 6, 2024
Date Accepted: Jun 17, 2025

The final, peer-reviewed published version of this preprint can be found here:

Evaluating a Chatbot as a Companion for Patients With Breast Cancer: Collaborative Pilot Study

Boie SD, Glastetter E, Lux MP, Balzer F, von Kalle C, Lenz C, Müller U

Evaluating a Chatbot as a Companion for Patients With Breast Cancer: Collaborative Pilot Study

JMIR Cancer 2025;11:e68426

DOI: 10.2196/68426

PMID: 40802992

PMCID: 12373300

Evaluating a Chatbot as Companion for Patients with Breast Cancer: A Collaborative Pilot Study

  • Sebastian Daniel Boie; 
  • Esther Glastetter; 
  • Michael Patrick Lux; 
  • Felix Balzer; 
  • Christof von Kalle; 
  • Christian Lenz; 
  • Ulrike Müller

ABSTRACT

Background:

A breast cancer diagnosis often leaves patients with numerous questions, underscoring the need for personalized, linguistically accessible information to facilitate adherence and shared decision-making. Despite the availability of high-quality information in oncology guidelines and other materials, the challenge remains to tailor this information to the specific needs of individual patients.

Objective:

This study investigates the potential of Artificial Intelligence, specifically Large Language Models like ChatGPT, to provide personalized answers to patient inquiries in German. We present 104 real patient questions, propose evaluation criteria and compile a list of relevant documents for chatbot development.

Methods:

We collaborated with one of Germany's largest breast cancer patient representation groups to gather frequently asked questions. We tailored a custom prompt for ChatGPT and compiled a comprehensive database of pertinent medical documents, including guidelines, recommendations, and informational materials, which we then uploaded to a vector store. This database enabled ChatGPT to retrieve relevant information in response to user queries. We tested our Chatbot implementation using these questions and evaluated its answers based on four criteria: comprehensibility, correctness, completeness, and potential to cause undue harm. Each criterion was assessed on a 5-point Likert scale.

Results:

Out of 118 questions received, 104 had a medical focus, with a high information need for endocrine-based therapies and side effect management. The questions and our performance evaluation can be used as a benchmark for development of German-speaking patient-centered chatbots. The chatbot performed well overall, with 86% of answers rated as comprehensible, 88% as correct, and 89% as not harmful. However, only 69% of answers included all relevant information, and 6% were potentially harmful, underscoring the need for supervision.

Conclusions:

AI-based chatbots with access to high quality information can effectively personalize information for patients, enhancing patient-centered communication in oncology. However, supervision by medical professionals is strongly recommended.


 Citation

Please cite as:

Boie SD, Glastetter E, Lux MP, Balzer F, von Kalle C, Lenz C, Müller U

Evaluating a Chatbot as a Companion for Patients With Breast Cancer: Collaborative Pilot Study

JMIR Cancer 2025;11:e68426

DOI: 10.2196/68426

PMID: 40802992

PMCID: 12373300

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.